The main objective of this study is to investigate the relationship between the number of cranial nerves passing through the cavernous sinus affected by a lesion and the percentage of lesions located in the cavernous sinus itself. We collected cases retrospectively and classified them into groups according to the number of involved cranial nerves. The diagnoses were confirmed either with MRI, angiography or pathological examination. Sixty-eight cases in total were collected. In the increasing order of cranial nerve involvement (from 1 to 4 nerves), 17.7, 44.4, 56.3 and 77.8% of cases were found to have lesions in the cavernous sinus. A linear regression model with a least square estimator showed an approximately linear correlation. We concluded that there was an approximately linear correlation between the number of cranial nerves affected by a lesion and the percentage of lesions located in the cavernous sinus.

Kline LB: Tolosa-Hunt syndrome. Surv Ophthalmol 1982;27:79–95.
Mathews NT, Chandy J: Painful ophthalmoplegia. J Neurol Sci 1970;11:243–256.
Keane JR: Cavernous sinus syndrome: Analysis of 151 cases. Arch Neurol 1996;53:967–971.
Sheldon MR: Introduction to Probability and Statistics for Engineers and Scientists. New York, Wiley & Sons, 1987.
Hunt WE: Tolosa-Hunt syndrome: One cause of painful ophthalmoplegia. J Neurosurg 1976;44:544–549.
Parkinson D: Sympathetic pathways. J Neurosurg 1994;81:809- 810.
Parkinson D, Johnston J, Chaudhuri A: Sympathetic connections to the fifth and sixth cranial nerves. Anat Rec 1978;191:221–226.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.